Clinical Trial Update: To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes [Phase 1]

View source ↗

Summary

It summarizes a completed Phase 1 trial assessing safety, tolerability, pharmacokinetics/pharmacodynamics, and the effect of fasting after a single oral dose of…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD5658 (AZD5658)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED